Genomic newborn screening. Perspective from the Ethics Commission of the Spanish Society for Human Genetics. Part II: Ethical, legal and social issues (ELSIs) of the introduction of next generation sequencing technologies in a Public Health newborn screen
e202203030
Keywords:
Newborn screening, Genomic newborn screening, Newborn sequencing, Public Health, Genomic Public Health, Next generation sequencing technologies, Ethical, legal and social issuesAbstract
Genome sequencing is a very attractive technology as it is also the idea of sequencing children at birth, with the aim to establish medical care and preventive actions during their whole life, tailored to the genome of each newborn.
Part I of this article analyses limitations and opportunities of next generation sequencing technologies (NGS). Part II relates scientific knowledge with ethical, legal and social issues (ELSIs) concerning its application to a newborn screening program. This program is offered universally to a vulnerable and asymptomatic population and must be guided by principles of “do not harm” and to act in the “best interest of child”.
With this purpose, this article considers, first of all, ethical principles of bioethics and public health that govern newborn screening. Then it summarizes main issues of our legal framework. And finally, in social context, it analyzes influences of technological imperative, commercial actors and patient´s advocacy groups, as well as parent’s perspective and psychosocial aspects.
In this context, conclusion is that whole genome sequencing should not be implemented as universal newborn screening. Nevertheless, the use of NGS could be an opportunity to extend these programs, including treatable infantile diseases that cannot be detected with other technologies. That means realizing a directed approach in order to identify well known genomic variants, highly penetrant, that confer a high risk of preventable or treatable diseases for which treatment must begin at the neonatal period.
The implementation of such directed genomic screening should follow current evidence based model for newborn screening. This model shows three features: recognition of the importance of the evaluation of empirical, epidemiological and clinical data before taking the decision to include a disease; evaluation of benefits and risks (proportionality) and evaluation of benefits and costs (distributive justice); and finally, consideration of public consensus, because this kind of decisions have a value that concerns society as a whole.
Downloads
References
Wilson JM, Jungner G. Principles and practice of screening for disease. Public health papers nº 34. World Health Organization. Geneva. 1968. http://whqlibdoc.who.int/php/WHO_PHP_34.pdf
Centers of Disease Control and Prevention (CDC). Ten great public health achievements worldwide, 2001-2010. Mmwr Morb Mortal Weekly Rep 2011; 60: 814-818.
Department of Health. Our inheritance our future. Realizing the potential of genetics in the NHS. June 2003. https://www.nuffieldtrust.org.uk/files/2019-11/genetics.pdf
Collins FS. The language of life. The DNA and the revolution in personalized medicine. Genom Soc Policy. 2010 Dec; 6(3): 82.
Human Genetics Commission and the UK National Screening Commitee. Profiling the newborn a prospective gene technology. March 2005. https://wellcomecollection.org/works/p4966r4p
Pàmpols Ros T, Pérez Aytés A, García Sagredo JM, Díaz de Bustamante A, Blanco Guillermo A. Cribado neonatal genómico. Perspectiva de la Comisión de ética de la Asociación Española de Genética humana. Parte I. Las tecnologías de secuenciación masiva (NGS) y su aplicación al cribado neonatal. Desafíos y oportunidades. Rev Esp Salud Pública. 2022; 96: 4 de febrero e202202012.
Howard CH, Knoppers BM, Cornel MC. Clayton EW, Sénécal K, Borry P endorsed by the European Society of Human Genetics; the P3G International Pediatric Platform; the Human Genome Organization; and the PHG Foundation. Whole-genome sequencing in newborn screening. A statement on the continued importance of targeted approaches in newborn screening programs. Eur J Hum Genet 2015; 23: 1593-1600.
Wilson C. Sequencing the genome of every UK baby would be an ethical minefield. New Scientist Magazine issue 3256, publicado 16 noviembre 2019. https://www.newscientist.com/article/2222754-sequencing-the-genome-of-every-uk-baby-would-be-an-ethical-minefield/
BSGM Executive Committee. Genome sequencing of healthy newborns. 12 November 2019. https://bsgm.org.uk/media/11578/bsgm-response-revised_genome-sequencing-of-healthy-newborns_revised.pdf
Johnston J, Koenig BA. Should we sequence the genome of every newborn? Scientific American January 3 2020 (https://blogs.scientificamerican.com/observations/should-we-sequence-the-genome-of-every-newborn/).
Sénécal K, Vears DF, Bertier G, Knoppers BM, Borry P. Genome-based newborn screening: a conceptual analysis of the best interests of the child standard. Per Med 2015; 12(5): 439-441.
Khoury M J, Scot Baren M, Clyne M, Dobron D, Gwinn ML, Fy Green R, Kolor K, Rodriguez JL, Wulf A, Yu W. From public health genomics to precision public health; a 20 years journey. Genetics in Medicine 2018; 20(6): 574-582.
Wald NJ. The definition of screening. J MedScr 2001; 8: 1.
Murray M, Giovani MA, Doyle DL, Harrison SM, et al and the American College of Medical Genetics and Genomics board of directors. DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMC). Genetics in medicine. 2021. https://doi.org/10.1038/s 41436-020-01082-w
Pàmpols Ros T, Pérez Aytés A, García Sagredo JM, Díaz de Bustamante A, Martín Arribas C, García López FJ, Nicolás Jiménez P, Dulín Iñiguez E, Labrador Cañadas MA. Medio siglo de cribado neonatal en España: evolución de los aspectos éticos, legales y sociales (AELS). Parte I. Aspectos éticos. Rev Esp Salud Pública. 2020; Vol 94: 17 de enero e202101.
President´s Council on Bioethics. The Changing moral focus on newborn screening: An ethical analysis by the president´s council on bioethics. Washington DC. 2008. https://bioethicsarchive.georgetown.edu/pcbe/reports/newborn_screening/
Tarini BA, Goldenberg AJ. Ethical issues in newborn screening in the genomic era. Annu Rev Genomics Hum Genet 2012; 12: 381-393.
Goldenberg AJ, Sharp RR. The ethical hazards and programmatic challenges of genomic newborn screening. JAMA 2012; 307(5): 461-462.
Dondorp WJ, DeWert GM. The “thousand-dollar-genome”: An ethical exploration. Eur J Hum Genet. 2013. 21: S6.
Morrisey C, Walker RL. The ethics of general population preventive genome sequencing: rights and social justice. J of Medicine and Philosophy. 2018. 43: 22-43.
Sénécal K, Unim B, Knoppers BM. Newborn Screening Programs: Next generation ethical and social issues. OBM Genetics. 2018; 283. doi:10.21926/obm.genetics.1803027
Knoppers BM, Chatwick R. Human genetic research: emerging trends in ethics. Nature Reviews genetics 2005; 6: 75-79.
Knoppers BM, Thorogood A, Chatwick R. The human genome organization: towards next generation ethics. Genome Medicine 2013; 5: 38.
Presidential Commission for the Study of Bioethical Issues. Privacy and progress in whole genome sequencing. Washington D.C. October 2012. https://bioethicsarchive.georgetown.edu/pcsbi/sites/default/files/PrivacyProgress508_1.pdf
Lightbody G, Haberland V, Browne L et al. Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application. Briefings in Bioinformatics. 2019; 20(5): 1795-1811.
Friedman JM, Cornel MC, Goldenberg AJ, Lister KJ, Sénécal K, Vears DF. The Global Alliance for Genomics and Health Regulatory and Ethics Working Group Paediatric Task Team. Genomic newborn screening: public health considerations and recommendations. BMC Medical Genomics 2017; 10: 9. DOI: 10.1186/s12920-017-0247-4.
Cornel M, Rigter T, Weinreich S, Burgard P, Hoffmann GF, Lindner M. Newborn Screening in Europe-Expert Opinion Document. EU Tender-Evaluation of population newborn screening practices for rare disorders in Member States of the European Union. 2017. https://www.isns-neoscreening.org/wp-content/uploads/2018/11/Expert-opinion-document-on-NBS-FINAL.pdf
European Commission EuroGentest. European workshop on genetic testing offer in Europe. 2013http://www.eurogentest.org/fileadmin/templates/eugt/pdf/News_documents/JRC_Genetic_testing_offer_in_Europe.pdf
Wright DC. Next steps in the sequence: The implications of whole genome sequencing for health in the UK: PHG Foundation. 2011. https://www.phgfoundation.org/media/140/download/Next%20steps%20in%20the%20sequence.pdf?v=1&inline=1
Health Council of the Netherlands. [New recommendations for the Dutch neonatal screening program. A report from the Health Council of the Netherlands]. Ned Tijdschrvoor Geneesk 2015; 159:A9115.
Societá Italiana di Pediatria (SIP), Societá Italiana de Neonatología (SIN), Societá Italiana Malattie Genetiche Pediatriche e Disabilitá (SIMGePeD), Societá Italiana de Genetica Umana (SIGU). Intersociety policy statement on the use of whole-exome sequencing in the critically ill newborn infant. Ital J Pediatr. 2017; 43: 100.
ACMG. Points to consider in the clinical application of genome sequencing. Genet Med Offic J Am Coll Med Genet. 2012; 14: 759-761.
Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA, and members of the NSIGHT Ethics and Policy Advisory Board. Sequencing newborns: A call for nuanced use of genomic technologies. In The ethics of sequencing newborns: Recommendations and Reflections, especial report. Hastings Center Report2018, 48,nº 4 S2+ [20 pages]. DOI: 10.1002/hast.874
The ethics of sequencing newborns: Recommendations and Reflections, especial report. Hastings Center Report 48, nº 4 (2018).
Pàmpols Ros, T, García Sagredo JM, Pérez Aytés A, Díaz de Bustamante A. Pruebas genéticas de venta directa a los consumidores. Perspectiva de la Comisión de Ética de la Asociación Española de Genética Humana. Med Clin (Barc) 2019; 153(1): 35-40.
Nuffield Council on Bioethics. Bioethics briefing note. Whole genome sequencing of babies. 2018.https://www.nuffieldbioethics.org/assets/pdfs/Whole-genome-sequencing-of-babies.pdf
Nicolás Jiménez P, Pàmpols Ros T, García López F, Martín Arribas C, Pérez Aytés A, García Sagredo JM, Díaz de Bustamante A, Dulín Iñiguez E, Labrador Cañadas MV. Medio siglo de cribado neonatal en España: evolución de los aspectos éticos, legales y sociales (AELS). Parte II, marco legal. RevEsp Salud Pública 2021; 95; 26 de enero e202101018.
Boletín Oficial del Estado. Ley 14/2007, de 3 de julio, de Investigación Biomédica. BOE núm. 159, de 04-07-2007. https://www.boe.es/eli/es/l/2007/07/03/14
UNESCO. Declaración internacional sobre datos genéticos humanos. UNESDOC de 16-10-2003. Artículo 2xii. https://unesdoc.unesco.org/ark:/48223/pf0000136112_spa
Council of Europe. Additional Protocol to the Convention on Human Rights and Biomedicine concerning Genetic Testing for Health Purposes. CETS Nº 203. Strasbourg, 27-11-2008. https://rm.coe.int/1680084824
Boletín Oficial del Estado. Orden SSI/2065/2014, de 31 de octubre, por la que se modifican los anexos I, II y III del Real Decreto 1030/2006 de 15 de septiembre por el que se establece la cartera de servicios comunes del Sistema Nacional de Salud y el procedimiento para su actualización. BOE núm.269, de 06-09-2014. https://www.boe.es/buscar/act.php?id=BOE-A-2006-16212
Grupo de trabajo en gestión de datos genómicos. Gestión de datos genómicos con finalidad clínica y de investigación. Instituto Roche. 2015. https://institutoroche.es/static/jornadas/archivos/gen_data.pdf
Boletín Oficial del Estado. Real Decreto 1716/2011, de 18 de noviembre, por el que se establecen los requisitos básicos de autorización y funcionamiento de los biobancos con fines de investigación biomédica y del tratamiento de las muestras biológicas de origen humano, y se regula el funcionamiento y organización del Registro Nacional de Biobancos para investigación biomédica. BOE núm. 290, de 02-12-2011. https://www.boe.es/buscar/doc.php?id=BOE-A-2011-18919
Gostin LO, Hodge Jr JG. Genetic privacy and the law: an end to genetics exceptionalism. 1999. 40 Jurimetrics J: 21-58.
Kosseim P; Letendre M and Knoppers BM. Protecting genetics information. A comparative normative approach. Gen Edit 2004; 2(1): 1-7.
Boletín Oficial de Estado. Ley Orgánica 15/1999 de 13 de diciembre, de Protección de Datos personales. BOE núm.298, de 14-12-1999. https://www.boe.es/buscar/act.php?id=BOE-A-1999-23750
Diario Oficial de la Unión Europea. Reglamento (UE) 2016/679 del Parlamento Europeo y del Consejo, de 27 de abril de 2016, relativo a la protección de las personas físicas en lo que respecta al tratamiento de sus datos personales y a la libre circulación de estos datos y por el que se deroga la Directiva 95/46/CE (Reglamento general de protección de datos. L 119, de 04-05-2016). https://www.boe.es/doue/2016/119/L00001-00088.pdf
Boletín Oficial del Estado. Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales. BOE núm. 294, de 06-12-2018. https://www.boe.es/eli/es/lo/2018/12/05/3
Universidad del País Vasco. Cátedra de derecho y genoma humano y Salut DPD. Sistema de salut de Catalunya. Generalitat de Catalunya. Edita Oficina del DPD-Fundació TIC SALUT SOCIAL. Barcelona julio de 2021. https://ticsalutsocial.cat/wp-content/uploads/2021/11/INFORME-PROYECTO-DATOS-GENETICOS.pdf
Agencia Española de Protección de Datos. Guía para clientes que contraten servicios de cloud computing. 2018. https://www.aepd.es/es/documento/guia-cloud-clientes.pdf-0
Thorogood A, Bobe J, Prainsak B, Middleton A et al. On the behalf of the Global Alliance for Genomics and Health. APPLaUD: access for patients and participants to individual level uninterpreted genomic data. Human Genomics 2018; 12:7.
Beauvais MJ, Thorogood AM; Szego MJ, Sénécal k, ZawatiM’n H, Knoppers BM. Parental access to children’s raw genomic data in Canada: legal rights and professional responsibility. Frontiers in genetics. Policy and practice reviews 2021; 2(article 535340): 1-17.
Narayanasany S, Markina V, Thorogood A, Blazkova A, Shahari M, Knoppers Bm, Prainsack B, Koesters R. Genomic sequencing capacity, data retention and personal access to raw data in Europe. Frontiers in genetics. Original research 2020, 11(article 303): 1-15.
Labrador Cañadas MV, Pàmpols Ros T, DulínIñíguez E, Pérez Aytés A, García Sagredo JM, Díaz de Bustamante A, Martín Arribas C, García López F, Nicolás Jiménez P. Medio siglo de cribado neonatal en España: Evolución de los aspectos éticos, legales y sociales (AELS). Parte III. Aspectos sociales. RevEsp Salud Pública 2021; 95: 26 de enero e202101016.
Koenig BA. The technological imperative in medical practice: The social creation of a “Routine treatment” en Biomedicine Examined. Dordrecht, Netherlands: Springer, 1988, 465-96, at 465.
Laberge AM, Burke W. Avoiding the technological imperative: Criteria for genetic screening programs. OBM Genetics 2017; 1(3). DOI: 10.21926/obm.genet.1703006
Frankel LA, Pereira S, McGuire AL. Potential psychosocial risks of sequencing newborns. Pediatrics 2016; 137, suppl1: e20153731F.
Khoury MJ, Berg AI, Coates R, Evans J, Teucht SM and Bradley LA. The evidence dilemma in genomic medicine. Health Affairs 2008; 27(6):1600-1611. DOI: 10.1377/hlthaff.27.6.1600
Wilfond BS, Thomson EJ. Models of public health genetic policy development. En Genetics and Public Health in the 21st century. Editado por MJ Khoury, W Burke and ES Thomson Oxford University Press 2000, chapter 4, 61-82.
Boletín Oficial del Estado. Real Decreto 1030/2006, de 15 de septiembre, por el que se establece la cartera de servicios comunes del sistema nacional de salud. BOE núm. 222, de 16-09-2006. https://www.boe.es/buscar/act.php?id=BOE-A-2006-16212
Taylor-Philips S, Stinton Ch, Ferrante di Rufano L, Seedat f, Clarke A, Deeks JJ. Association between use of systematic review and national policy recommendations on screening newborn babies for rare diseases: Systematic review and metanalysis. BMJ 2018; 360:K1612.
Borry P, Sénécal K, Knoppers BM. Do it yourself newborn screening. JAMA Pediatrics 2016; 170(6): 523-524.
https://southgenetics.com/babygenes/
“Introducing Sema 4 Natalis” en https://sema4genomics.com/products/natalis
“My Newborn DNA” / Veritas Intercontinental” en www.Veritasint.com
Ceyhan-Birsoy O, Murry JB, Machini K et al. Interpretation of genomic sequencing results in healthy and ill newborns: Results from de BabySeq project. Am J Hum Genet 2019;
: 76-93.
Ceyhan-Birsoy JB, Machini K, Lebo MS et al. A curated gene list for reporting results of newborn genomic sequencing. Genet Med 2017; 19(7): 809-818.
Berg JS, Agrawal PB, Bayley DB et al. Newborn screening in genomic medicine and public health. Pediatrics 2017; 139(2): e20162252.
Nuffield Council on Bioethics. Medical profiling and online medicine: The ethics of “personalized healthcare” in a consumer age. 2010 https://www.nuffieldbioethics.org/assets/pdfs/Medical-profiling-and-online-medicine-the-ethics-of-personalised-healthcare-in-a-consumer-age.pdf
Genetic Alliance UK. Fixing the present. Building for the future. Newborn screening for rare conditions. July 2019. https://geneticalliance.org.uk/wp-content/uploads/2020/01/Newborn-Screening-Report.pdf
Bayley DB Jr, Beskow LM, Davis AM, Skinner B. Changing perspectives on the benefits of newborn screening. MRDD research Review 2006; 12: 270-279.
Grob R. Is my child healthy? Is my child sick? : Changing parental experiences of cystic fibrosis in the age of expanded screening. Social Sciences & medicine 2008; 67: 1056-1064.
Johnston J, Juengst E. Are parents obligated to learn as much as possible about their children genomes? In The ethics of sequencing newborns: Recommendations and Reflections. Special report. Hastings Center Reports 2018, 48, nº4. DOI: 10.1002/hast.877
Anderson JA, Meyn MS, Shuman C, ZlotnikShaul R, Mantella LE, Szego MS, Monfared N, Hayeems RR. Parents perspectives on whole genome sequencing for their children: qualified enthusiasm?. Journal of Medical Ethics 2017; 43: 540-542.
Fernandez CV, Bouffet E, Malkin D, Jabado N et al. Attitudes of parents toward the return of targeted and incidental genomic research in children. Genetics in Medicine 2014; 16(8): 633-640.
Evans JP. Return of results to the families of children in genomic sequencing: tallying risks and benefits. Genetics in Medicine. 2013, 15(6): 435-436.
Lewis MA Pakin RS, Roche MY, Furberg RD et al. Supporting parental decisions about genomic sequencing: The NC Nexus decision aid. Pediatrics 2016; 137(s1): e 20153731.E.
Waisbren SE, Bäck DK, Lin Ch, Kalia SS, Ringer SA, Holm IA, Green RC. Parents are interested in genomic testing during the early postpartum period. GenetMed 2015; 17(6): 501-504.
Goldenberg AJ, Dodson DS, Davis MM, Tarini B. Parent’s interest in whole-genome sequencing of newborns. Genetics in Medicine 2014; 16(1): 78-84.
Bombard Y, Miller FA, Hayeems RZ, Barg G et al. Public views on participating in newborn screening using genome sequencing. Eur J Hum Genet 2014 ; 22, 1248-1254.
Pereira S, Robinson JA, Gutierrez AM, Petersen DK et al. Perceived benefits, risks and utility of newborn genomic sequencing in the BabySeq project. Pediatrics 2019; 143 (S1) e 20181099C.
Genetti CA, Schwartz TS, Robinson JO, Grace E et al. Parental interests in genomic sequencing of newborn: Enrollment experience from the BabySeq project. Genet Med 2019, 21(3): 622-630.
Pampols T, Terracini B, de Abajo FJ, Feito L, Martín-Arribas MC, Fernández JM, Redondo T, Campos J, Herrera J, Júdez J, Abascal A, Morales A. Recomendaciones sobre los aspectos éticos de los programas de cribado de población para enfermedades raras. Rev Esp Salud Pública2010; 84: 121-136.
Grupo de trabajo de protocolos de cribado neonatal. Ponencia de Cribado Poblacional de la Comisión de Salud Pública. Requisitos y recomendaciones para el desarrollo de programas de cribado neonatal de la comisión de salud pública. Ministerio de Sanidad Consumo y Bienestar Social. Septiembre 2019. https://www.sanidad.gob.es/en/profesionales/saludPublica/prevPromocion/Cribado/docs/CribadoNeonatal_EnfEndocrinometabolicas.pdf
Lewis MA, Bonhome N, Bloss CS. A new era, new strategies: Education and communication strategies to manage greater access to genomic information. In The ethics of sequencing newborns: Recommendations and Reflections, especial report. Hastings Center Report 48, nº4 (2018): S25-S27. DOI: 10.1002/hast.874
Genomics England. NHS. Newborn Genomes Programme. Continuing the conversation about offering whole genome sequencing (WGS) for all newborns. September 2021 (Accesible en www.genomicsengland.co.uk).
Genomics England. UK national Screening Committee. Implications of whole genome sequencing for newborn screening. A public dialogue. A Findings Report Hopkins Van Mil. July 2021.
Downloads
Published
How to Cite
License
Copyright (c) 2022 Teresa Pàmpols Ros, Antonio Pérez Aytés, José Miguel García Sagredo, Aránzazu Díaz de Bustamante, Ignacio Blanco Guillermo
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
![¿Cómo evaluar para la RESP? [PARA REVISORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-revisores-0eaa113abcbc4fc554c7c6c7840ca4c6.jpg)
![¿Cómo recibir avisos sobre nuevos artículos de la RESP? [PARA LECTORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-lectores-aa689338e95aab07df45b4b0d583188f.jpg)
